Evidence map›Paper›PMID 32492044›Full record

Trial reportPLoS pathogens2020

HIV-1 variants are archived throughout infection and persist in the reservoir.

Kelsie Brooks, Bradley R Jones, Dario A Dilernia, Daniel J Wilkins, Daniel T Claiborne, Samantha McInally, Jill Gilmour, William Kilembe, Jeffrey B Joy, Susan A Allen and 2 more

Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 55 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. HIV Cure: How Far We Have Come?Indian journal of microbiology · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Kelsie BrooksEmory Vaccine Center, Emory University, Atlanta, Georgia, United States of America.ORCID 0000-0002-4758-2429
Bradley R JonesBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Dario A DilerniaEmory Vaccine Center, Emory University, Atlanta, Georgia, United States of America.
Daniel J WilkinsEmory Vaccine Center, Emory University, Atlanta, Georgia, United States of America.ORCID 0000-0003-0398-8715
Daniel T ClaiborneEmory Vaccine Center, Emory University, Atlanta, Georgia, United States of America.
Samantha McInallyEmory Vaccine Center, Emory University, Atlanta, Georgia, United States of America.
Jill GilmourHuman Immunology Lab, International AIDS Vaccine Initiative, London, England, United Kingdom.
William KilembeZambia-Emory HIV Research Project, Lusaka, Zambia.
Jeffrey B JoyBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Susan A AllenZambia-Emory HIV Research Project, Lusaka, Zambia.ORCID 0000-0002-9150-3898
Zabrina L BrummeBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.ORCID 0000-0002-8157-1037
Eric HunterEmory Vaccine Center, Emory University, Atlanta, Georgia, United States of America.ORCID 0000-0002-4273-8631
Emory University · USAIDS Vancouver · CAInternational HIV/AIDS Alliance · GBSimon Fraser University · CAUniversity of British Columbia · CA

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral EradicationUM1AI126617 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD, NIXON, DOUGLAS F · 2016 to 2020
$28.1M
CTL and HIV Polymorphisms in Heterosexual TransmissionR01AI064060 · NIAID · EMORY UNIVERSITY · PI GOEPFERT, PAUL A., HUNTER, ERIC · 2005 to 2019
$21.7M
Virologic Correlates of Heterosexual TransmissionR01AI051231 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ALLEN, TODD M, HUNTER, ERIC · 2002 to 2022
$9.9M
Genetics, dynamics and fitness of the HIV-1 latent reservoirR21AI127029 · NIAID · SIMON FRASER UNIVERSITY · PI BROCKMAN, MARK ALAN, BRUMME, ZABRINA · 2018 to 2019
$300k
The Impact of HIV-1 Transmitted/Founder Virus on the Viral ReservoirF31AI122926 · NIAID · EMORY UNIVERSITY · PI BROOKS, KELSIE LIZBETH · 2016 to 2018
$132k
CIHR PJT-159625NIAID NIH HHS F31 AI122926NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI051231NIAID NIH HHS R01 AI064060NIAID NIH HHS R21 AI127029NIAID NIH HHS UM1 AI126617NIH HHS P51 OD011132
6 · The paper itself

Abstract

The HIV-1 reservoir consists of latently infected cells that persist despite antiretroviral therapy (ART). Elucidating the proviral genetic composition of the reservoir, particularly in the context of pre-therapy viral diversity, is therefore important to understanding reservoir formation and the persistence of latently infected cells. Here we investigate reservoir proviral variants from 13 Zambian acutely-infected individuals with additional pre-therapy sampling for a unique comparison to the ART-naïve quasispecies. We identified complete transmitted/founder (TF) viruses from seroconversion plasma samples, and additionally amplified and sequenced HIV-1 from plasma obtained one year post-infection and just prior to ART initiation. While the majority of proviral variants in the reservoir were most closely related to viral variants from the latest pre-therapy time point, we also identified reservoir proviral variants dating to or near the time of infection, and to intermediate time points between infection and treatment initiation. Reservoir proviral variants differing by five or fewer nucleotide changes from the TF virus persisted during treatment in five individuals, including proviral variants that exactly matched the TF in two individuals, one of whom had remained ART-naïve for more than six years. Proviral variants during treatment were significantly less divergent from the TF virus than plasma variants present at the last ART-naïve time point. These findings indicate that reservoir proviral variants are archived throughout infection, recapitulating much of the viral diversity that arises throughout untreated HIV-1 infection, and strategies to target and reduce the reservoir must therefore permit for the clearance of proviruses encompassing this extensive diversity.

Indexed as

Genetic VariationPhylogenyAcute DiseaseAdultAnti-Retroviral AgentsFemaleHIV-1HIV InfectionsHumansMaleMiddle AgedZambiaAnti-Retroviral Agents

Identifiers

PMID32492044
PMCPMC7295247
OpenAlexW3030327683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.